TET3 and serous adenocarcinoma: The overall survival was significant shorter in advanced stage (III-IV) patients with high TET3 expression ((HR = 1.37 (1.06–1.78), P = 0.016, n = 387, Fig. 3e), and also significant shorter in high-grade serous adenocarcinoma with early stage(I-II) (HR = 5.55 (1.17–26.31), P = 0.017, n = 42, Fig. 3f).